Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

NCT01945762 · clinicaltrials.gov ↗

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic, Aggressive, Sporadic, Unresectable, Locally
Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Interventions

DRUG: Vandetanib 300 mg

Sponsor

Genzyme, a Sanofi Company

Collaborators

[object Object]